1. Pong K, Zaleska MM. Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. Curr Drug Targets CNS Neurol Disord. 2003 Dec;2(6):349-56.
2. Borlongan CV, Emerich DF, Hoffer BJ, Bartus RT.
Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity. Brain Res. 2002 Nov 29;956(2):211-20.
3. Udina E, Navarro X. [Immunophilins: neuroprotective agents and promoters of neural regeneration]. Neurologia. 2002 Apr;17(4):200-13.
4. Gold BG. Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders. Expert Opin Investig Drugs. 2000 Oct;9(10):2331-42.
5. Castilho RF, Hansson O, Brundin P. FK506
and cyclosporin A enhance the survival of cultured and grafted rat embryonic
dopamine neurons. Exp. Neurol. 2000;164(1):94-101.
6. Costantini LC, Isacson O. Immunophilin
ligands and GDNF enhance neurite branching or elongation from developing
dopamine neurons in culture. Exp Neurol 2000;164(1):60-70.
7. Berman SB, Hastings TG. Dopamine
oxidation alters mitochondrial respiration and induces permeability
transition in brain mitochondria: implications for Parkinson's disease.
J. Neurochem. 1999;73(3):1127-37.
8. Borlongan CV, Stahl CE, Fujisaki T, Sanberg PR, Watanabe S. Cyclosporine
A-induced hyperactivity in rats: is it mediated by immunosuppression,
neurotrophism, or both? Cell Transplant 1999;8(1):153-9.
9. Cassarino DS, Parks JK, Parker WD, Jr., Bennett JP, Jr. The
parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition
pore and releases cytochrome c in isolated mitochondria via an oxidative
mechanism. Biochim Biophys Acta 1999;1453(1):49-62.
10. Chalmers-Redman RM, Fraser AD, Carlile GW, Pong A, Tatton WG. Glucose
protection from MPP+-induced apoptosis depends on mitochondrial membrane
potential and ATP synthase. Biochem Biophys Res Commun 1999;257(2):440-7.
11. Honey CR, Shen H. Immunosuppression
for neural xenografts: a comparison of cyclosporin and anti-CD25 monoclonal
antibody. J Neurosurg 1999;91(1):109-13.
12. Seaton TA, Cooper JM, Schapira AH. Cyclosporin
inhibition of apoptosis induced by mitochondrial complex I toxins.
Brain Res 1998;809(1):12-7.
13. Snyder SH, Sabatini DM, Lai MM, Steiner JP, Hamilton GS, Suzdak PD.
Neural
actions of immunophilin ligands. Trends Pharmacol Sci 1998;19(1):21-6.
14. Tatton WG, Chalmers-Redman RM. Mitochondria
in neurodegenerative apoptosis: an opportunity for therapy? Ann
Neurol 1998;44(3 Suppl 1):S134-41.
15. Lopez-Lozano JJ, Bravo G, Brera B, et al. Regression
of parkinsonian fetal ventral mesencephalon grafts upon withdrawal of
cyclosporine A immunosuppression. The CPH Neural Transplantation Group.
Transplant Proc 1997;29(1-2):977-80.
16. Matsuura K, Kabuto H, Makino H, Ogawa N. Initial
cyclosporin A but not glucocorticoid treatment promotes recovery of
striatal dopamine concentration in 6-hydroxydopamine lesioned mice.
Neurosci Lett 1997;230(3):191-4.
17. Matsuura K, Makino H, Ogawa N. Cyclosporin
A attenuates the decrease in tyrosine hydroxylase immunoreactivity in
nigrostriatal dopaminergic neurons and in striatal dopamine content
in rats with intrastriatal injection of 6- hydroxydopamine. Exp
Neurol 1997;146(2):526-35.
18. Sabatini DM, Lai MM, Snyder SH. Neural
roles of immunophilins and their ligands. Mol Neurobiol 1997;15(2):223-39.
19. Borlongan CV, Freeman TB, Hauser RA, Cahill DW, Sanberg PR. Cyclosporine-A
increases locomotor activity in rats with 6- hydroxydopamine-induced
hemiparkinsonism: relevance to neural transplantation. Surg Neurol
1996;46(4):384-8.
20. Matsuura K, Kabuto H, Makino H, Ogawa N. Cyclosporin
A attenuates degeneration of dopaminergic neurons induced by 6-hydroxydopamine
in the mouse brain. Brain Res 1996;733(1):101-4.
21. Borlongan CV, Freeman TB, Scorcia TA, et al. Cyclosporine-A
increases spontaneous and dopamine agonist-induced locomotor behavior
in normal rats. Cell Transplant 1995;4(1):65-73.
22. Howard MAd, Dacey RG, Jr., Winn HR. Brain
xenografts: the effect of cyclosporin A on graft survival. J
Neurosurg 1988;69(1):121-6.
